Waters Co. (NYSE:WAT) Receives Consensus Recommendation of “Hold” from Brokerages

Waters Co. (NYSE:WAT) has been given a consensus recommendation of “Hold” by the fourteen research firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $213.73.

A number of research analysts have recently commented on WAT shares. TheStreet cut Waters from a “b” rating to a “c+” rating in a research report on Tuesday, October 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Waters in a research report on Tuesday, October 29th. Stifel Nicolaus started coverage on Waters in a research report on Thursday. They set a “hold” rating and a $210.00 price target on the stock. Barclays cut Waters from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $210.00 to $195.00 in a research report on Wednesday, October 9th. Finally, Robert W. Baird upped their price target on Waters from $208.00 to $217.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th.

WAT stock opened at $217.32 on Monday. The stock’s fifty day simple moving average is $216.51 and its two-hundred day simple moving average is $213.81. The company has a current ratio of 2.25, a quick ratio of 1.63 and a debt-to-equity ratio of 11.40. Waters has a 1-year low of $173.41 and a 1-year high of $255.21. The stock has a market cap of $13.76 billion, a P/E ratio of 26.21, a P/E/G ratio of 2.54 and a beta of 1.04.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, October 29th. The medical instruments supplier reported $2.13 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.13. Waters had a return on equity of 77.73% and a net margin of 23.98%. The business had revenue of $577.28 million for the quarter, compared to analysts’ expectations of $588.35 million. During the same quarter in the previous year, the firm earned $1.92 earnings per share. The business’s revenue was down .1% on a year-over-year basis. As a group, analysts forecast that Waters will post 8.83 earnings per share for the current fiscal year.

In related news, SVP Elizabeth B. Rae sold 29,326 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $213.12, for a total transaction of $6,249,957.12. Following the sale, the senior vice president now directly owns 23,932 shares in the company, valued at approximately $5,100,387.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Laurie H. M.D. Glimcher sold 2,200 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $214.64, for a total value of $472,208.00. Following the sale, the director now owns 3,600 shares in the company, valued at $772,704. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,901 shares of company stock worth $7,228,491. 1.14% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Diversified Trust Co raised its stake in shares of Waters by 2.3% during the 3rd quarter. Diversified Trust Co now owns 2,230 shares of the medical instruments supplier’s stock valued at $498,000 after purchasing an additional 50 shares during the period. Eqis Capital Management Inc. increased its stake in Waters by 2.4% in the 3rd quarter. Eqis Capital Management Inc. now owns 2,139 shares of the medical instruments supplier’s stock worth $478,000 after acquiring an additional 50 shares during the last quarter. Cadence Capital Management LLC increased its stake in Waters by 1.0% in the 2nd quarter. Cadence Capital Management LLC now owns 5,622 shares of the medical instruments supplier’s stock worth $1,210,000 after acquiring an additional 53 shares during the last quarter. GHP Investment Advisors Inc. increased its stake in Waters by 0.8% in the 2nd quarter. GHP Investment Advisors Inc. now owns 8,272 shares of the medical instruments supplier’s stock worth $1,780,000 after acquiring an additional 65 shares during the last quarter. Finally, Advisor Partners LLC increased its stake in Waters by 3.6% in the 3rd quarter. Advisor Partners LLC now owns 2,027 shares of the medical instruments supplier’s stock worth $453,000 after acquiring an additional 70 shares during the last quarter. Institutional investors own 99.56% of the company’s stock.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Recommended Story: What is diluted earnings per share (Diluted EPS)?

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.